128 related articles for article (PubMed ID: 15816329)
1. Rho proteins and vascular diseases.
Pacaud P; Sauzeau V; Loirand G
Arch Mal Coeur Vaiss; 2005 Mar; 98(3):249-54. PubMed ID: 15816329
[TBL] [Abstract][Full Text] [Related]
2. Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II.
Ohtsu H; Mifune M; Frank GD; Saito S; Inagami T; Kim-Mitsuyama S; Takuwa Y; Sasaki T; Rothstein JD; Suzuki H; Nakashima H; Woolfolk EA; Motley ED; Eguchi S
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1831-6. PubMed ID: 15994438
[TBL] [Abstract][Full Text] [Related]
3. Ste20-related kinase SLK phosphorylates Ser188 of RhoA to induce vasodilation in response to angiotensin II Type 2 receptor activation.
Guilluy C; Rolli-Derkinderen M; Loufrani L; Bourgé A; Henrion D; Sabourin L; Loirand G; Pacaud P
Circ Res; 2008 May; 102(10):1265-74. PubMed ID: 18420945
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Rho proteins by phosphorylation in the cardiovascular system.
Loirand G; Guilluy C; Pacaud P
Trends Cardiovasc Med; 2006 Aug; 16(6):199-204. PubMed ID: 16839863
[TBL] [Abstract][Full Text] [Related]
5. RHO SIGNALING in vascular diseases.
Seasholtz TM; Brown JH
Mol Interv; 2004 Dec; 4(6):348-57. PubMed ID: 15616164
[TBL] [Abstract][Full Text] [Related]
6. New drug targets for pulmonary hypertension: Rho GTPases in pulmonary vascular remodelling.
Wojciak-Stothard B
Postgrad Med J; 2008 Jul; 84(993):348-53. PubMed ID: 18716013
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II up-regulates the leukemia-associated Rho guanine nucleotide exchange factor (RhoGEF), a regulator of G protein signaling domain-containing RhoGEF, in vascular smooth muscle cells.
Ying Z; Jin L; Palmer T; Webb RC
Mol Pharmacol; 2006 Mar; 69(3):932-40. PubMed ID: 16354763
[TBL] [Abstract][Full Text] [Related]
8. Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases.
Hu E; Lee D
Curr Opin Investig Drugs; 2003 Sep; 4(9):1065-75. PubMed ID: 14582450
[TBL] [Abstract][Full Text] [Related]
9. Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension.
Xing XQ; Gan Y; Wu SJ; Chen P; Zhou R; Xiang XD
Drug News Perspect; 2006 Nov; 19(9):517-22. PubMed ID: 17220956
[TBL] [Abstract][Full Text] [Related]
10. [Rho/Rho kinase signal transduction pathway in cardiovascular disease and cardiovascular remodeling].
Jalil J; Lavandero S; Chiong M; Ocaranza MP
Rev Esp Cardiol; 2005 Aug; 58(8):951-61. PubMed ID: 16053829
[TBL] [Abstract][Full Text] [Related]
11. Rho-kinase is an important therapeutic target in cardiovascular medicine.
Shimokawa H; Takeshita A
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1767-75. PubMed ID: 16002741
[TBL] [Abstract][Full Text] [Related]
12. Redox signaling in hypertension.
Paravicini TM; Touyz RM
Cardiovasc Res; 2006 Jul; 71(2):247-58. PubMed ID: 16765337
[TBL] [Abstract][Full Text] [Related]
13. The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration.
Lepley D; Paik JH; Hla T; Ferrer F
Cancer Res; 2005 May; 65(9):3788-95. PubMed ID: 15867375
[TBL] [Abstract][Full Text] [Related]
14. Different migration of vascular smooth muscle cells from human coronary artery bypass vessels. Role of Rho/ROCK pathway.
Weiss S; Frischknecht K; Greutert H; Payeli S; Steffel J; Lüscher TF; Carrel TP; Tanner FC
J Vasc Res; 2007; 44(2):149-56. PubMed ID: 17264516
[TBL] [Abstract][Full Text] [Related]
15. Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway.
Kozai T; Eto M; Yang Z; Shimokawa H; Lüscher TF
Cardiovasc Res; 2005 Dec; 68(3):475-82. PubMed ID: 16098957
[TBL] [Abstract][Full Text] [Related]
16. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease.
Budzyn K; Marley PD; Sobey CG
Trends Pharmacol Sci; 2006 Feb; 27(2):97-104. PubMed ID: 16376997
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiological role of the vascular smooth muscle cell.
Michel JB; De Roux N; Plissonnier D; Anidjar S; Salzmann JL; Levy B
J Cardiovasc Pharmacol; 1990; 16 Suppl 1():S4-11. PubMed ID: 1706013
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of vascular smooth muscle cell migration.
Gerthoffer WT
Circ Res; 2007 Mar; 100(5):607-21. PubMed ID: 17363707
[TBL] [Abstract][Full Text] [Related]
19. Essential role for class II phosphoinositide 3-kinase alpha-isoform in Ca2+-induced, Rho- and Rho kinase-dependent regulation of myosin phosphatase and contraction in isolated vascular smooth muscle cells.
Yoshioka K; Sugimoto N; Takuwa N; Takuwa Y
Mol Pharmacol; 2007 Mar; 71(3):912-20. PubMed ID: 17179444
[TBL] [Abstract][Full Text] [Related]
20. Development of Rho-kinase inhibitors for cardiovascular medicine.
Shimokawa H; Rashid M
Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
